No results for ‘’
Natco Pharma Ltd
₹815.35
(0.40%)
Thu, 17 Sept 2026, 00:40 pm
Health Technology
Pharmaceuticals: Major
24.5KNatco Pharma Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 15.36 | 13.56 | 5.87 | 3.08 | 7.51 | 14.38 | 17.23 | 18.73 | 24.78 | 51.92 | 44.84 | 30.39 | 19.28 | 16.39 | 20.04 | 34.15 | 81.26 | 14.38 | 12.30 | 7.58 |
| Price to book ratio | 2.45 | 2.23 | 1.09 | 0.52 | 1.23 | 2.18 | 2.34 | 2.52 | 3.63 | 8.29 | 5.54 | 8.95 | 4.53 | 2.99 | 2.44 | 3.65 | 3.24 | 2.11 | 2.91 | 1.88 |
| Price to sales ratio | 2.17 | 1.71 | 0.73 | 0.31 | 0.83 | 1.69 | 1.99 | 2.18 | 3.64 | 8.91 | 6.86 | 7.40 | 6.22 | 5.12 | 4.88 | 8.89 | 7.24 | 3.81 | 4.29 | 3.24 |
| Price to cash flow ratio | 11.41 | 10.17 | 5.77 | 5.55 | 5.99 | 14.46 | 26.55 | 42.04 | 23.08 | 110.73 | 80.32 | 43.74 | 29.30 | 15.03 | 19.14 | 42.65 | 173.76 | 11.64 | 13.64 | 7.81 |
| Enterprise value | 421Cr | 466Cr | 312Cr | 239Cr | 494Cr | 957Cr | 1253Cr | 1685Cr | 2788Cr | 7292Cr | 7055Cr | 14861Cr | 13346Cr | 9890Cr | 8656Cr | 14514Cr | 13466Cr | 9336Cr | 15669Cr | 11758Cr |
| Enterprise value to EBITDA ratio | 27.60 | 13.95 | 5.84 | 3.30 | 5.53 | 10.14 | 11.93 | 14.45 | 19.71 | 41.30 | 25.51 | 21.40 | 14.52 | 12.25 | 15.08 | 53.90 | 54.19 | 9.63 | 8.61 | 5.23 |
| Debt to equity ratio | 0.54 | 0.42 | 0.43 | 0.49 | 0.39 | 0.62 | 0.56 | 0.64 | 0.34 | 0.37 | 0.09 | 0.13 | 0.06 | 0.11 | 0.08 | 0.06 | 0.10 | 0.04 | 0.06 | 0.04 |
| Return on equity % | 0 | 18.57 | 20.33 | 18.42 | 17.80 | 16.26 | 14.47 | 14.31 | 16.31 | 17.13 | 14.46 | 32.98 | 29.49 | 19.64 | 12.69 | 11.17 | 4.05 | 15.66 | 25.88 | 28.01 |
Natco Pharma Ltd Enterprise Value
The Natco Pharma Ltd Enterprise Value is a key financial metric used by investors to evaluate Natco Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Natco Pharma Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Natco Pharma Ltd (NSE: NATCOPHARM, BSE: 524816) is currently trading at ₹815.35, with a market capitalization of ₹14669.1Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Natco Pharma Ltd Enterprise Value is essential for fundamental analysis.
Natco Pharma Ltd Enterprise Value Current Value
The current Natco Pharma Ltd Enterprise Value stands at 11758Cr.
The Natco Pharma Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Natco Pharma Ltd Enterprise Value Historical Trend
The Natco Pharma Ltd Enterprise Value has shown the following historical trend:
- 2024: 11758Cr
- 2023: 15669Cr
- 2022: 9336Cr
- 2021: 13466Cr
- 2020: 14514Cr
The decline in Natco Pharma Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Natco Pharma Ltd Enterprise Value Indicates for Investors
The Natco Pharma Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Natco Pharma Ltd.
Natco Pharma Ltd Enterprise Value Analysis Summary
The Natco Pharma Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Natco Pharma Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Natco Pharma Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.